Cancer Letters
Volume 223, Issue 2 , Pages 249-258 , 8 June 2005

Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells

Received 7 April 2004 ,Accepted 20 October 2004.

References 

  1. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta. 1998;1400:173–184
  2. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer. 1998;34:1514–1521
  3. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol. 1994;34:191–218
  4. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature. 1996;379:225–232
  5. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994;12:530–542
  6. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63:2705–2715
  7. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1996;1287:77–102
  8. Lai SL, Perng RP, Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J. Biomed. Sci. 2000;7:64–70
  9. Israels LG, Israels ED. Apoptosis. Stem Cells. 1999;17:306–313
  10. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2000;21:477–484
  11. Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur. J. Biochem. 2001;2682784–2682791
  12. Poele RHte, Joel SP. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br. J. Cancer. 1999;p53:1285–1293
  13. Poele RHte, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62:1876–1883
  14. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109:335–346
  15. Cui H, Schroering A, Ding HF. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol. Cancer Ther. 2002;1:679–686
  16. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992;7:171–180
  17. Alexandre S, Rast C, Nguyen-Ba G, Vasseur P. Detection of apoptosis induced by topoisomerase inhibitors and serum deprivation in syrian hamster embryo cells. Exp. Cell Res. 2000;255:30–39
  18. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015
  19. Harley CB, Kim WN, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol. 1994;59:307–315
  20. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA. 1995;92:9363–9367
  21. Gartel AL, Tyner AL. The Role of the Cyclin-dependent Kinase Inhibitor p21 in Apoptosis. Mol. Cancer Ther. 2002;1:639–649
  22. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for Cyclin-Dependent Kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell Biol. 1999;19:2109–2117
  23. Pines J, Hunter T. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. Eur. Mol. Biol. Org. J. 1994;13:3772–3781
  24. Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. 2003;63:8563–8572
  25. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999;104:63–69
  26. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 2002;277:35509–35515
  27. Michishita E, Nakabayashi K, Ogino H, Suzuki ST, Fujii M, Ayusawa D. DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts. Biochem. Biophys. Res. Commun. 1998;253:667–671
  28. Hayflick L. The limited in vitro life time of human diploid cell strains. Exp. Cell Res. 1965;37:614–636
  29. Linskens MH, Harley CB, West WM, Campisi J, Hayflick L. Replicative senescence and cell death. Science. 1995;267:17
  30. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol. 2000;35:317–329
  31. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999;59:3761–3767
  32. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene. 1999;18:2789–2797
  33. Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl Acad. Sci. USA. 1997;94:9648–9653
  34. Ling YH, Zou Y, Perez-Soler R. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res. 2000;20:693–702
  35. Higginbottom K, Cummings M, Newland AC, Allen PD. Etoposide-mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival. Br. J. Haematol. 2002;119:956–964
  36. Pavey S, Russell T, Gabrielli B. G2 phase cell cycle arrest in human skin following UV irradiation. Oncogene. 2001;20:6103–6110
  37. Christov KT, E S, Kim VE, Steele RA. Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours. Eur. J. Cancer. 2003;392:30–39
  38. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett. 2003;194:209–219
  39. Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, et al. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res. 1999;59:2957–2964
  40. Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood. 2000;95:2645–2650
  41. DeJesus V, Rios I, Davis C, Chen Y, Calhoun D, Zakeri Z, et al. Induction of apoptosis in human replicative senescent fibroblasts. Exp. Cell Res. 2002;274:92–99
  42. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 2002;277:17154–17160
  43. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin. Cancer Res. 2003;9:2856–2865
  44. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001;61:5843–5849
  45. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957–1963

PII: S0304-3835(04)00856-0

doi: 10.1016/j.canlet.2004.10.049

Cancer Letters
Volume 223, Issue 2 , Pages 249-258 , 8 June 2005

Article Tools

* Image Usage & Resolution